DOI: https://doi.org/10.14710/dmj.v13i1.37533

Clinicopathological Profile Of Her2 Positive (Non-Luminal) Breast Cancer Subtype At Haji Adam Malik General Hospital From 2020-2021

*Yosua Natanael  -  Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia 20222., Indonesia
Denny Rifsal Siregar  -  Division of Surgical Oncology, Department of Surgery, Universitas Sumatera Utara, Indonesia
Kamal Basri Siregar  -  Division of Surgical Oncology, Department of Surgery, Universitas Sumatera Utara, Indonesia
Lili Rohmawati  -  Department of Paediatrics, Universitas Sumatera Utara, Indonesia

Citation Format:
Abstract

Background: Breast cancer is one of the cancers with the highest prevalence in Indonesia. According to GLOBOCAN data for 2020, the number of breast cancer cases reached 68,858 (16.6%) cases out of a total of 396,914 new cancer cases in Indonesia. There are many factors that can trigger cancer with different clinical manifestations and subtypes from one event to another, so researchers are interested in researching the profile of breast cancer patients with the HER2 subtype at H. Adam Malik General Hospital in 2020-2021.

Objective: In the present study, we aim to determine the clinicopathological profile of Her2 positive (non-luminal) breast cancer subtype patients at Haji Adam Malik General Hospital from 2020-2021.

Methods: The method used in this study is descriptive quantitative with total sampling technique. The data samples was obtained from medical records of breast cancer patient with her2 positive (non-luminal) subtype which was then sorted according to the availability of characteristic needed for this study.

 

Results: majority of breast cancer patients with her2 positive (non-luminal) subtype at H Adam Malik General Hospital in 2020-2021 was within the age group of > 50 years, with all married status. the BMI of the majority of patients (68.6%) was normal weight, all respondent admit there was no family history diagnosed with cancer (100%), majority tumor size (52,9%) is >5 cm, with most patients having cancer metastasized to 1-3 lymph nodes (54,9%), distant metastases only in 39,2% of the total sample observed, majority (35,3%) histopathological degree is in grade 1 and grade 3 , the histopathological classification of the majority (86,3%) was IDC type.

 

Conclusion: Overall there is diversity of frequencies within the observed clinicopathological characteristics.

Fulltext View|Download
Keywords: Breast cancer; Her2 positive; non luminal; profile

Article Metrics:

Article Info
Section: Original Articles
Language : EN
Recent articles
The Association Between Exclusive Breastfeeding and the Occurrence of Stunting Among Children Aged 12-60 Months in Community Health Centers in Yogyakarta City Comparison of Hatha Yoga and Elderly Exercise in Functional Balance of the Elderly INCIDENT OF DRY EYE IN FK UNDIP STUDENTS USING SMARTPHONES More recent articles
  1. Kementrian Kesehatan Republik Indonesia. Paduan Penatalaksanaan Kanker Payudara, KEMENKES, 2018. Available at: http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf. [Accessed 17 May 2022]
  2. Warjianto, M., Soewoto, W., Alifianto, U., & Wujoso, H. Hubungan Reseptor Estrogen, Reseptor Progesteron dan Ekspresi Her-2/Neu Dengan Grading Histopatologi pada Pasien Kanker Payudara di RSUD dr. SMedJour, 2020; 3(2). https://doi.org/10.13057/smj.v3i1.35228
  3. Wangsa, I. G., et al. Gambaran stadium dan jenis histopatologi kanker payudara di Subbagian Bedah Onkologi RSUP Sanglah Denpasar tahun 2015-2016. CrossMark, 2018;9. https://doi.org/10.1556/ism.v9i1.165
  4. INFODATIN. Breast cancer basic info. Kemenkes.com. 2021. Available at: https://pusdatin.kemkes.go.id/folder/view/01/structure-publikasi-pusdatin-info-datin.html. [Accessed 5 June 2022]
  5. Shoemaker, M. L., White, M. C., Wu, M., Weir, H. K., & Romieu, I. Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013. NIH, 2018 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955792/ Breast cancer research and treatment. [Retrieved November 28, 2022]
  6. Akbar, ali and eka. Hubungan Usia Terhadap Derajat Diferensiasi Kanker Payudara Pada Wanita. Semarang, Indonesia: Jurnal Kedokteran Diponegoro, 2016
  7. Lei, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Beijing, China: Cancer Communication, 2021
  8. Megawati, P.M. & Sri, R.R. Determinan Kejadian Kanker Payudara pada Wanita Usia Subur (15-49 Tahun). Semarang, Indonesia: Indonesian Journal of Public Health and Nutrition, 2021
  9. Meng, lin. et al. Does marital status correlate with the female breast cancer risk? A systematic review and meta-analysis of observational studies. U.S. National Library of Medicine, 2020. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058335/ (Accessed: November 1, 2022)
  10. Prawirohardjo, et al. Hubungan Index Massa Tubuh Dengan Grading Pada Kanker Payudara. Surakarta, Indonesia: Biomedika, 2018
  11. Kang, Liu. et al. Association between body mass index and breast cancer risk: Evidence based on a dose-response meta-analysis, Cancer management and research. U.S. National Library of Medicine, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783020/ (Accessed: December 1, 2022)
  12. Lei, L. et al. Correlation between family history and characteristics of breast cancer, Scientific reports. U.S. National Library of Medicine, 2021 Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973811/ (Accessed: November 27, 2022)
  13. Ketut, S. & Sari, L.M. Kanker Payudara: Diagnostik, Faktor Risiko, Dan Stadium. 1st edn. Bali, Indonesia: Ganesha Medicine Journal, 2022
  14. Mochamad, A.S. Profil Penderita Kanker Payudara Stadium Lanjut Baik Lokal Maupun Metastasis Jauh Di Rsup Hasan Sadikin Bandung. Malang, Indonesia: Farmasains. (2018). Available at: https://doi.org/10.22219/far.v1i2.1168/ (Accessed: November 27, 2022)
  15. Siregar, K.B. HER2 overexpression in Relation to breast cancer histopathological Grading : A promising prognostic and predictive biomarker for breast cancer. Journal of health, medicine and nursing, (2015). vol.21. ISSN 2422-8419. [Accessed 22 Dec 2022]
  16. Nakashima K, Uematsu T, Takahashi K, Nishimura S, Tadokoro Y, Hayashi T, Sugino T. Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. Breast Cancer. 2019 Mar;26(2):206-214. Available from: doi: 10.1007/s12282-018-0914-0.Epub2018Sep26.PMID:30259332
  17. Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, Cordovana A, Farina G, Bramati A, Piva S, Dazzani MC, Paternò E, La Verde NM. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLoS One. 2017 Dec 6;12(12). Available from: doi: 10.1371/journal.pone.0189127.PMID:29211792;PMCID:PMC5718505
  18. Ivan, E. et al. Breast cancer in Young Women: Pathologic and immunohistochemical features, Acta clinica Croatica. U.S. National Library of Medicine, (2018) Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536281/ (Accessed: November 25, 2022)
  19. Kristina, J. et al. Er, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-reduced CK5 expression in metastases, Breast cancer : basic and clinical research. U.S. National Library of Medicine,. 2013 Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579427/ (Accessed: November 20, 2022)
  20. Susanti, Melya. Et al. Profil Kanker Payudara Di Rsup Dr M Djamil Padang Pada Tahun 2019. 1st edn. Padang, Indonesia: Nusantara Hasanah Journal, . 2022; (1)
  21. Jialiang, Y. et al. Prediction of her2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via Multimodal Deep Learning, Computational and structural biotechnology journal. U.S. National Library of Medicine, 2021. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733169/ (Accessed: November 19, 2022)
  22. Arciero CA, Guo Y, Jiang R, Behera M, O'Regan R, Peng L, Li X. ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer. Clin Breast Cancer. 2019 Aug;19(4):236-245. Available from: doi: 10.1016/j.clbc.2019.02.001.Epub2019Feb14.PMID:30846407
  23. Wang, R. et al. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer, BMC cancer. U.S. National Library of Medicine, 2019. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852913/ (Accessed: November 28, 2022)
  24. Suhyun, L. et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography, Medicine. U.S. National Library of Medicine, 2016. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402599/ (Accessed: November 27, 2022)

Last update:

No citation recorded.

Last update:

No citation recorded.